Navigation Links
AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
Date:8/11/2009

other 2,952 2,207 4,092 4,013 ------------------------------------------------------------------------- 8,379 10,457 14,490 20,205 ------------------------------------------------------------------------- Operating expenses Cost of sales 4,545 4,758 8,239 9,362 Research and development costs, net of tax credits and grants 12,076 17,345 23,513 31,034 Selling, general and administrative 3,102 6,606 6,656 11,010 Depreciation and amortization Property, plant and equipment 331 397 642 766 Intangible assets 563 876 1,120 1,716 ------------------------------------------------------------------------- 20,617 29,982 40,170 53,888 ------------------------------------------------------------------------- Loss from operations (12,238) (19,525) (25,680) (33,683) ------------------------------------------------------------------------- Other income (expenses) Interest income 118 311 274 588 Interest expense - (53) (2) (68) Foreign exchange (loss) gain (960) (502) (60) 1,753 Loss on disposal of long-lived assets held for sale - (810) - (35) ------------------------------------------------------------------------- (842) (1,054) 212 2,238 ------------------------------------------------------------------------- Net loss for the period (13,080) (20,579) (25,468) (31,445) ---------
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... Production of high tenacity filament yarn of ... in the EU. For instance, it surpassed the EUR 106 million mark (in value ... 2010. Germany is a major producer, while Italy is a key consumer. , ...
(Date:7/27/2015)... -- Research presented at the 2015 AACC Annual Meeting ... that led to a fingerprick Ebola test becoming the ... receive approval from the World Health Organization (WHO). This ... West Africa by identifying suspected ... isolate and treat these patients much faster than is ...
(Date:7/27/2015)... YORK , July 27, 2015 ... today announced the winners of its annual Klerman ... research by scientists who have been supported by ... career scientists to pursue innovative ideas in neurobiological ... "proof" of concept for the early detection, treatment, ...
(Date:7/27/2015)... ... 27, 2015 , ... Visual Assay was named as a finalist for the ... technologies and services of the past year. More than 70 judges selected the finalists, ... will be announced at the 2015 R&D 100 Awards Dinner on November 13 at ...
Breaking Biology Technology:High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2
... ITMN ) today announced that Daniel G. Welch, Chairman, ... Deutsche,Bank,s 2008 Biotech Boston Confab on November 11, 2008 ... audio webcast of the presentation, investors and other,interested parties ... InterMune,s,corporate website at http://www.intermune.com . The company recommends,logging ...
... Human Genome Sciences,Inc. (Nasdaq: HGSI ) announced ... Confab will be webcast and may be accessed at, ... A member of Human Genome Sciences, senior management team ... at 2:50 PM Eastern Time., Investors interested in ...
... that its executives will be speaking at the following,investor conferences, and ... Credit Suisse Global Health Care Conference, Phoenix, AZ ... Time, Piper Jaffray Health Care Conference, ... 2008 at 2.00 p.m. Eastern Time Accessing Webcasts, To ...
Cached Biology Technology:Cepheid to Webcast Upcoming Financial Presentations 2
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
(Date:6/29/2015)... , June 24, 2015 ... of the "Latin America Biomedical Sensors Market - ... offering. The Latin America Biomedical Sensors market ... CAGR of 2.04% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
(Date:6/25/2015)... June 25, 2015  TAKE Solutions Ltd., a global ... the United States Patent and Trademark Office (USPTO) for ... leverages TAKE Solutions, Clinical Accelerators to reduce the time ... compared to standardization without the accelerators), thus reducing time ... At the heart of the patented Clinical ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2
... have found a way to pull pure oxygen from ... and a room-temperature glass of water. ,Because oxygen ... using solar electricity to split water into those elements--a ... One of the chief obstacles to that green-energy scenario ...
... United States, Lyme disease is the most frequently reported ... These animal-borne diseases can make people very sick, and ... crucial to protecting the public. Scientists at the Cary ... $750,000 in grant funding from the U.S. Environmental Protection ...
... University of New Hampshire researchers have tagged one ... They are the first free-swimming leatherbacks ever tagged in ... an endangered species, were tagged July 17, 26 and ... tracking data, allowing scientists to better understand these elusive, ...
Cached Biology News:Water refineries? 2Water refineries? 3EPA funds ground-breaking Lyme disease research 2UNH researchers tag first-ever free-swimming leatherback turtles in New England 2UNH researchers tag first-ever free-swimming leatherback turtles in New England 3
Enables rapid purification of double-stranded DNA fragments = 200 bp, including, for example, PCR reaction products, DNA fragments obtained in restriction enzyme digests, or double-stranded cDNA...
Silica bead method is an economic method of DNA extraction from agarose...
5 minutes from gel band to purified DNA...
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-MSC 2 x 109 cells...
Biology Products: